{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:24:46Z","timestamp":1760189086256},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Important studies challenging previous approaches to the treatment of adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia (ALL) have emerged in the past decade. Donor versus no donor comparisons of allogeneic transplant highlight a potent graft-versus-leukemia effect in ALL, and the application of reduced-intensity conditioning transplants may exploit this effect while reducing non-relapse mortality. The adoption of the use of pediatric intensity-type regimens in adolescents and young adults shows promise to improve outcomes in this population. New therapeutic targets such as mutations in NOTCH1 in T-cell ALL and CD22 in pre-B ALL are being exploited in clinical trials. The application of molecular techniques and flow cytometry to quantitate minimal residual disease will allow further stratification of patients by risk. Although the outcomes of adults with ALL lag behind the stunningly successful results seen in children, new paradigms and new discoveries bring hope that this disparity will steadily lessen.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.362","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"362-370","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Evolving paradigms in the therapy of Philadelphia chromosome\u2013negative acute lymphoblastic leukemia in adults"],"prefix":"10.1182","volume":"2009","author":[{"given":"Mark R.","family":"Litzow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111706432675000_R1","doi-asserted-by":"crossref","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030\u20131043.","DOI":"10.1016\/S0140-6736(08)60457-2"},{"key":"2019111706432675000_R2","doi-asserted-by":"crossref","unstructured":"Fielding A. The treatment of adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2008;381\u2013389.","DOI":"10.1182\/asheducation-2008.1.381"},{"key":"2019111706432675000_R3","unstructured":"Fiere D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1993;11:1990\u20132001."},{"key":"2019111706432675000_R4","doi-asserted-by":"crossref","unstructured":"Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1994;12:2580\u20132587.","DOI":"10.1200\/JCO.1994.12.12.2580"},{"key":"2019111706432675000_R5","doi-asserted-by":"crossref","unstructured":"Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075\u20134086.","DOI":"10.1200\/JCO.2004.10.050"},{"key":"2019111706432675000_R6","doi-asserted-by":"crossref","unstructured":"Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer. 2006;106:2657\u20132663.","DOI":"10.1002\/cncr.21932"},{"key":"2019111706432675000_R7","doi-asserted-by":"crossref","unstructured":"Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006;12:1\u201330.","DOI":"10.1016\/j.bbmt.2005.10.018"},{"key":"2019111706432675000_R8","doi-asserted-by":"crossref","unstructured":"Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood. 2008;111:1827\u20131833.","DOI":"10.1182\/blood-2007-10-116582"},{"key":"2019111706432675000_R9","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 2009;113:1375\u20131382.","DOI":"10.1182\/blood-2008-07-168625"},{"key":"2019111706432675000_R10","doi-asserted-by":"crossref","unstructured":"Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:303\u2013306.","DOI":"10.3324\/haematol.11960"},{"key":"2019111706432675000_R11","doi-asserted-by":"crossref","unstructured":"Mohty M, Labopin M, Ruutu T, et al. Reduced intensity versus conventional myeloablative conditioning (RIC vs. MAC) allogeneic stem cell transplantation (allo-SCT) for patients wtih acute lymphoblastic leukemia (ALL): A survey from the acute leukemia working party of EBMT [abstract]. Blood. 2008;112:294. Abstract #783,","DOI":"10.1182\/blood.V112.11.793.793"},{"key":"2019111706432675000_R12","doi-asserted-by":"crossref","unstructured":"Goldstone AH, Rowe JM. Transplantation in adult ALL. Hematology Am Soc Hematol Educ Program. 2009:593\u2013602.","DOI":"10.1182\/asheducation-2009.1.593"},{"key":"2019111706432675000_R13","doi-asserted-by":"crossref","unstructured":"Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646\u20131654.","DOI":"10.1182\/blood-2008-01-130237"},{"key":"2019111706432675000_R14","doi-asserted-by":"crossref","unstructured":"Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774\u2013780.","DOI":"10.1200\/JCO.2003.02.053"},{"key":"2019111706432675000_R15","doi-asserted-by":"crossref","unstructured":"deBont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18:2032\u20132035.","DOI":"10.1038\/sj.leu.2403538"},{"key":"2019111706432675000_R16","doi-asserted-by":"crossref","unstructured":"Hallbo\u0308o\u0308k H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107:1551\u20131561.","DOI":"10.1002\/cncr.22189"},{"key":"2019111706432675000_R17","doi-asserted-by":"crossref","unstructured":"Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials. Pediatr Blood Cancer. 2007;48:254\u2013261.","DOI":"10.1002\/pbc.20749"},{"key":"2019111706432675000_R18","doi-asserted-by":"crossref","unstructured":"Testi AM, Valsecchi MG, Conter V, et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols [abstract]. Blood. 2004;104:539. Abstract #1954.","DOI":"10.1182\/blood.V104.11.1954.1954"},{"key":"2019111706432675000_R19","doi-asserted-by":"crossref","unstructured":"Usvasalo A, Raty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica. 2008;93:1161\u20131168.","DOI":"10.3324\/haematol.12466"},{"key":"2019111706432675000_R20","doi-asserted-by":"crossref","unstructured":"Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21:760\u2013761.","DOI":"10.1200\/JCO.2003.11.116"},{"key":"2019111706432675000_R21","doi-asserted-by":"crossref","unstructured":"Rytting M, Pharm ME, Dour D, Muiera B, Advani A, Bleyer A. Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase [abstract]. Blood. 2008;112:672. Abstract #1924.","DOI":"10.1182\/blood.V112.11.1924.1924"},{"key":"2019111706432675000_R22","doi-asserted-by":"crossref","unstructured":"Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26:1843\u20131849.","DOI":"10.1200\/JCO.2007.13.7265"},{"key":"2019111706432675000_R23","doi-asserted-by":"crossref","unstructured":"Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911\u2013918.","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"2019111706432675000_R24","doi-asserted-by":"crossref","unstructured":"Thomas DA, O\u2019Brien S, Rytting M, et al. Acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) after frontline therapy with hyper-CVAD regimens [abstract]. Blood. 2008;112:674. Abstract #1930.","DOI":"10.1182\/blood.V112.11.1930.1930"},{"key":"2019111706432675000_R25","doi-asserted-by":"crossref","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408\u20131411.","DOI":"10.1182\/blood-2008-06-164863"},{"key":"2019111706432675000_R26","doi-asserted-by":"crossref","unstructured":"Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189\u20133197.","DOI":"10.1182\/blood-2006-10-051912"},{"key":"2019111706432675000_R27","doi-asserted-by":"crossref","unstructured":"Meijerink JP, den Boer ML, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol. 2009;46:16\u201323.","DOI":"10.1053\/j.seminhematol.2008.09.006"},{"key":"2019111706432675000_R28","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758\u2013764.","DOI":"10.1038\/nature05690"},{"key":"2019111706432675000_R29","doi-asserted-by":"crossref","unstructured":"Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113:3918\u20133924.","DOI":"10.1182\/blood-2008-10-184069"},{"key":"2019111706432675000_R30","doi-asserted-by":"crossref","unstructured":"Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program. 2009.","DOI":"10.1182\/asheducation-2009.1.353"},{"key":"2019111706432675000_R31","doi-asserted-by":"crossref","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009:113:6330\u20136337.","DOI":"10.1182\/blood-2008-04-151860"},{"key":"2019111706432675000_R32","unstructured":"Thomas DA, Kantarjian HM, Faderl S, et al. Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) [Abstract 1931]. Blood. 2008;112:674."},{"key":"2019111706432675000_R33","unstructured":"Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res. 2003;9:3991S\u20133994S."},{"key":"2019111706432675000_R34","doi-asserted-by":"crossref","unstructured":"Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: phase I\/II clinical trial results. Clin Cancer Res. 2004;10:5327\u20135334.","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"2019111706432675000_R35","doi-asserted-by":"crossref","unstructured":"Micallef I, Maurer M, Nikcevich D. A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma [abstract]. J Clin Oncol. 2008;25:454S. Abstract #8500.","DOI":"10.1200\/jco.2008.26.15_suppl.8500"},{"key":"2019111706432675000_R36","doi-asserted-by":"crossref","unstructured":"Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group pilot study. J Clin Oncol. 2008;26:3756\u20133762.","DOI":"10.1200\/JCO.2007.15.3528"},{"key":"2019111706432675000_R37","doi-asserted-by":"crossref","unstructured":"Kurtzberg J. The long and winding road of the clinical development of Nelarabine. Leuk Lymphoma. 2007;48:1\u20132.","DOI":"10.1080\/10428190601135447"},{"key":"2019111706432675000_R38","doi-asserted-by":"crossref","unstructured":"DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136\u20135142.","DOI":"10.1182\/blood-2006-11-056754"},{"key":"2019111706432675000_R39","unstructured":"Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer\u2014Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591\u2013598."},{"key":"2019111706432675000_R40","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52\u201358.","DOI":"10.1182\/blood-2002-01-0006"},{"key":"2019111706432675000_R41","doi-asserted-by":"crossref","unstructured":"Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116\u20131123.","DOI":"10.1182\/blood-2005-07-2708"},{"key":"2019111706432675000_R42","doi-asserted-by":"crossref","unstructured":"Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153\u20134162.","DOI":"10.1182\/blood-2008-11-185132"},{"key":"2019111706432675000_R43","doi-asserted-by":"crossref","unstructured":"Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009;46:100\u2013106.","DOI":"10.1053\/j.seminhematol.2008.09.001"},{"key":"2019111706432675000_R44","doi-asserted-by":"crossref","unstructured":"Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009;144:468\u2013483.","DOI":"10.1111\/j.1365-2141.2008.07513.x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/362\/645581\/362_370ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/362\/645581\/362_370ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T06:22:12Z","timestamp":1590301332000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/362\/19876\/Evolving-paradigms-in-the-therapy-of-Philadelphia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.362","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}